Save
Email
Print
ShareScienceDaily (Mar. 11, 2010) — Scientists may have uncovered a mechanism for resistance to paclitaxel in ovarian cancer, microRNA-31, suggesting a possible therapeutic target for overcoming chemotherapy resistance.
Mohamed K. Hassan, Ph.D., a postdoctoral fellow at Hokkaido University in Japan, completed the research as a collaborative study with his colleagues when he was a professional assistant in South Valley University in Egypt. Results of this study were presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held March 7-10, 2010.
"MicroRNAs do not code protein, but they regulate other proteins' expression," said Hassan. "So identifying any microRNA as responsible for chemoresistance is, in fact, introducing a real reason for the mechanism."
Ovarian cancer is typically responsive to chemotherapy with paclitaxel, but sometimes cancer cell lines become resistant, which renders chemotherapy useless. Hassan's research team analyzed a set of microRNAs and identified microRNA-31 as being responsible for this chemoresistance. MicroRNA-31 regulates the protein IFITM-1.
"We need to further verify this observation in clinical ovarian cancer samples and find a way to inhibit this target protein to improve the effect of paclitaxel and prevent the risk of recurrence," he said.
Recommend this story on Facebook, Twitter,
and Google +1:
Other bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by American Association for Cancer Research, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
more 
